Read the summary here: IMAPAC Insights

Key Oligo & ADC Advances: What 2025 is Really Saying

The world of biopharma is evolving faster than ever, with oligonucleotides and ADCs taking centre stage in the fight against complex diseases. As we move deeper into 2025, these 2 fields aren’t just growing, they’re transforming the very way we think about targeted therapies.

‍

Oligos: Precision Meets Innovation

2024 was a landmark year for oligonucleotide therapeutics, marked by breakthrough FDA approvals like Imetelstat (Rytelo™), a first-in-class telomerase inhibitor, and Olezarsen (Tryngolza™), which targets familial chylomicronaemia syndrome with a cutting-edge liver delivery platform. 

These advances aren’t just about new drugs; they’re about reimagining how we design and deliver therapies with next-level chemistry and technologies.

 Yet, despite this momentum, challenges remain, especially in reaching tissues beyond the liver. The industry is racing to perfect delivery systems that can tackle the central nervous system, muscles, and other tough targets.

 On the manufacturing front, innovations like liquid-phase oligonucleotide synthesis and enzymatic RNA production hint at a future where scaling up is faster, cleaner, and more sustainable. The market is poised to almost double by 2029, and the CDMO segment looks ready to explode, reaching nearly $18.4 billion by 2034.

ADCs: The New Frontier of Precision Oncology

Meanwhile, ADCs continue to redefine cancer treatment, combining the targeting power of antibodies with potent payloads that strike cancer cells while sparing healthy tissue. 2025 has already seen promising approvals like Datopotamab Deruxtecan (Dato-DXd) and label expansions for Enhertu®, pushing the boundaries of efficacy and safety.

The science behind ADCs is evolving rapidly, with innovations in linker technologies, bispecific antibodies, and dual-payload designs enabling therapies that are smarter and more effective. The industry’s confidence is reflected in the staggering $64 billion in ADC deals inked last year and major investments like Samsung Biologics’ new ADC manufacturing facility.

Looking Ahead: Hybrid Modalities & Patient-Centric Innovation

What’s next? 

The lines between oligos and antibodies are blurring with hybrid modalities like Antibody-Oligo Conjugates (AOCs); a convergence promising unprecedented precision. 

Advances in AI and continuous manufacturing will accelerate discovery and delivery, while the patient experience takes centre stage with innovations like at-home oligo injections and safer ADC profiles.

‍

Why the Antibody & TIDES Summit 2025 Matters

All these breakthroughs demand a forum that’s equally focused and forward-thinking. The Antibody & TIDES Summit 2025 in Amsterdam (09 & 10 September 2025) is designed for just that - a premium, intimate space where innovators gather across 3 sharp streams: Antibody Engineering, ADC Connect, and TIDES of Innovation.

This isn’t your typical conference. It’s a platform for real conversations, real collaborations, and real progress, capped at 300 attendees to keep it purposeful and powerful.

If you want to shape the future of biologics, this is where you need to be. 

View the agenda and secure your seat at the table - Antibody & TIDES Summit 2025